SCHEMBL6553676

SCHEMBL6553676

[c]1ccc(N(Cc2ccccc2)C2CCCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
G6PC1 P35575 1/20 0.44
DRD2 P14416 1/20 0.41
AGER Q15109 3/20 0.41
MTNR1A P48039 1/20 0.41
SLC6A2 P23975 6/20 0.40
SLC6A4 P31645 6/20 0.40
SLC6A3 Q01959 6/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK1 P28482 1/20 0.39
S1PR1 P21453 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
SLC18A3 Q16572 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10891206 0.89 G6PC1 (0.50) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL4476467 0.89 G6PC1 (0.54) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL9057596 0.81 AGER (0.57) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL8809151 0.81 AGER (0.57) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL9057640 0.81 CYP2C19 (0.53) G6PC1DRD2SLC6A2SLC6A4SLC6A3
SCHEMBL28104378 0.81 G6PC1 (0.48) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL8806703 0.81 G6PC1 (0.48) G6PC1DRD2AGERMTNR1ASLC6A2
SCHEMBL6553674 0.78 G6PC1 (0.44) G6PC1AGERMTNR1ASLC6A2SLC6A4
SCHEMBL11693064 0.76 S1PR1 (0.48) G6PC1DRD2SLC6A2SLC6A4SLC6A3
SCHEMBL8809383 0.76 SLC6A2 (0.43) G6PC1DRD2AGERMTNR1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1192065-C Oligo-methine colouring matter CLARIANT FINANCE BVI LTD (GB) 2005-03-09 CN disclosed
EP-1234007-B1 OLIGOMERIC METHINE DYES CLARIANT FINANCE BVI LTD (VG) 2004-02-18 EP disclosed
CN-1390247-A Oligo-methine colouring matter CLARIANT FINANCE BVI LTD (VG) 2003-01-08 CN disclosed
EP-1234007-A1 OLIGOMERIC METHINE DYES Clariant Finance (BVI) Limited (VG) 2002-08-28 EP disclosed
US-20010012899-A1 Oligomeric methine dyes CLARIANT FINANCE ( BVI) LIMITED 2001-08-09 US disclosed
WO-2001036543-A1 OLIGOMERIC METHINE DYES CLARIANT FINANCE (BVI) LIMITED (VG) 2001-05-25 WO disclosed
US-4256458-A DIMERIC PYRIDINIUM DYES BASF AKTIENGESELLSCHAFT (DE) 1981-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010012899-A1 Oligomeric methine dyes INMT, DDT, DDC G6PC1 4832/4885DRD2 41/4885AGER 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.